{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:33Z","timestamp":1791216033202,"version":"4.1.0"},"reference-count":31,"publisher":"BMJ","issue":"9","funder":[{"name":"Ricerca Corrente funding from Italian Ministry of Health to IRCCS Policlinico San Donato"},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2022,12,28]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A small but significant reduction in left ventricular (LV) mass after 18 months of migalastat treatment has been reported in Fabry disease (FD). This study aimed to assess the effect of migalastat on FD cardiac involvement, combining LV morphology and tissue characterisation by cardiac magnetic resonance (CMR) with cardiopulmonary exercise testing (CPET).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sixteen treatment-na\u00efve patients with FD (4 women, 46.4\u00b116.2 years) with cardiac involvement (reduced T1 values on CMR and\/or LV hypertrophy) underwent ECG, echocardiogram, troponin T and NT-proBNP (N-Terminal prohormone of Brain Natriuretic Peptide) assay, CMR with T1 mapping, and CPET before and after 18 months of migalastat.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No change in LV mass was detected at 18 months compared to baseline (95.2 g\/m<jats:sup>2<\/jats:sup> (66.0\u2013184.0) vs 99.0 g\/m<jats:sup>2<\/jats:sup> (69.0\u2013121.0), p=0.55). Overall, there was an increase in septal T1 of borderline significance (870.0 ms (848\u2013882) vs 860.0 ms (833.0\u2013875.0), p=0.056). Functional capacity showed an increase in oxygen consumption (VO<jats:sub>2<\/jats:sub>) at anaerobic threshold (15.50 mL\/kg\/min (13.70\u201321.50) vs 14.50 mL\/kg\/min (11.70\u201318.95), p=0.02), and a trend towards an increase in percent predicted peak VO<jats:sub>2<\/jats:sub> (72.0 (63.0\u201380.0) vs 69.0 (53.0\u201377.0), p=0.056) was observed. The subset of patients who showed an increase in T1 value and a reduction in LV mass (n=7, 1 female, age 40.5 (28.6\u201376.0)) was younger and at an earlier disease stage compared to the others, and also exhibited greater improvement in exercise tolerance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In treatment-na\u00efve FD patients with cardiac involvement, 18-month treatment with migalastat stabilised LV mass and was associated with a trend towards an improvement in exercise tolerance. A tendency to T1 increase was detected by CMR. The subset of patients who had significant benefits from the treatment showed an earlier cardiac disease compared to the others.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03838237\">NCT03838237<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmg-2022-108768","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T13:21:32Z","timestamp":1674220892000},"page":"850-858","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of Migalastat on cArdiac InvOlvement in FabRry DiseAse: MAIORA study"],"prefix":"10.1136","volume":"60","clinical-trial-number":[{"clinical-trial-number":"nct03838237","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03838237","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-0496","authenticated-orcid":false,"given":"Antonia","family":"Camporeale","sequence":"first","affiliation":[{"name":"Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandera","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan, Milano, Italy"},{"name":"University Cardiology Department, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Donato Hospital, Arezzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, San Gerardo Hospital, Monza, Italy"},{"name":"Department of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Spada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bersano","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Econimo","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Spedali Civili Hospital, ASST Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Lanzillo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Policlinico Casilino, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rubino","sequence":"additional","affiliation":[{"name":"Inherited and Rare Cardiovascular Disease, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Department, Infermi Hospital, Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Motta","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tanini","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, University Hospital Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rea","family":"Valaperta","sequence":"additional","affiliation":[{"name":"Operative Unit of Laboratory Medicine 1 - Clinical Pathology, Department of Pathology and Laboratory Medicine, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin","family":"Chow","sequence":"additional","affiliation":[{"name":"Siemens Medical Solutions USA, Malvern, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Baroni","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Cardiovascular Department, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Boveri","sequence":"additional","affiliation":[{"name":"Scientific Directorate, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Graziani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pica","sequence":"additional","affiliation":[{"name":"Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Tondi","sequence":"additional","affiliation":[{"name":"Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guazzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences for Health, University of Milan, Milano, Italy"},{"name":"Cardiology Division, San Paolo Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Multimodality Cardiac Imaging Section, IRCCS Policlinico San Donato, San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2025100511581099000_60.9.850.1","doi-asserted-by":"crossref","unstructured":"Desnick RJ , Ioannou YA , Eng CM . \u03b1-Galactosidase A Deficiency: Fabry Disease. In: The metabolic and molecular bases of inherited disease. 7th. New York, NY: McGraw-Hill, 2001.","DOI":"10.1006\/rwgn.2001.0443"},{"key":"2025100511581099000_60.9.850.2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in fabry disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025100511581099000_60.9.850.3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase arreplacement therapy in fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100511581099000_60.9.850.4","doi-asserted-by":"crossref","unstructured":"Schiffmann R , Kopp JB , Austin HA , et al . Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 2001;285 doi:10.1001\/jama.285.21.2743","DOI":"10.1001\/jama.285.21.2743"},{"key":"2025100511581099000_60.9.850.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510198"},{"key":"2025100511581099000_60.9.850.6","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-104178"},{"key":"2025100511581099000_60.9.850.7","doi-asserted-by":"crossref","unstructured":"Lenders M , Nordbeck P , Kurschat C , et al . Treatment of fabry disease with migalastat-outcome from a prospective 24 months observational multicenter study (famous). Eur Heart J Cardiovasc Pharmacother 2021;pvab025. doi:10.1093\/ehjcvp\/pvab025","DOI":"10.1093\/ehjcvp\/pvab025"},{"key":"2025100511581099000_60.9.850.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.09.017"},{"key":"2025100511581099000_60.9.850.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.07.741"},{"key":"2025100511581099000_60.9.850.10","doi-asserted-by":"crossref","unstructured":"Pica S , Sado DM , Maestrini V , et al . Reproducibility of native myocardial T1 mapping in the assessment of fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2014;16 doi:10.1186\/s12968-014-0099-4","DOI":"10.1186\/s12968-014-0099-4"},{"key":"2025100511581099000_60.9.850.11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of ffabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"2025100511581099000_60.9.850.12","doi-asserted-by":"crossref","unstructured":"Kawel-Boehm N , Maceira A , Valsangiacomo-Buechel ER , et al . Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 2015;17. doi:10.1186\/s12968-015-0111-7","DOI":"10.1186\/s12968-015-0111-7"},{"key":"2025100511581099000_60.9.850.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00219.x"},{"key":"2025100511581099000_60.9.850.14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfw082"},{"key":"2025100511581099000_60.9.850.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"2025100511581099000_60.9.850.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.012"},{"key":"2025100511581099000_60.9.850.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs221"},{"key":"2025100511581099000_60.9.850.18","doi-asserted-by":"crossref","unstructured":"Pedrizzetti G , Claus P , Kilner PJ , et al . Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson 2016;18. doi:10.1186\/s12968-016-0269-7","DOI":"10.1186\/s12968-016-0269-7"},{"key":"2025100511581099000_60.9.850.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.05.011"},{"key":"2025100511581099000_60.9.850.20","doi-asserted-by":"crossref","unstructured":"Piechnik SK , Ferreira VM , Dall\u2019Armellina E , et al . Shortened modified l look-llocker inversion recovery (shmolli) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010;12. doi:10.1186\/1532-429X-12-69","DOI":"10.1186\/1532-429X-12-69"},{"key":"2025100511581099000_60.9.850.21","doi-asserted-by":"crossref","unstructured":"Messroghli DR , Moon JC , Ferreira VM , et al . Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the european association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson 2017;19. doi:10.1186\/s12968-017-0389-8","DOI":"10.1186\/s12968-017-0389-8"},{"key":"2025100511581099000_60.9.850.22","doi-asserted-by":"crossref","unstructured":"Captur G , Gatehouse P , Keenan KE , et al . A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance-the T 1 mmapping and ECV standardization in cardiovascular magnetic resonance (T1MES) program. J Cardiovasc Magn Reson 2016;18 doi:10.1186\/s12968-016-0280-z","DOI":"10.1186\/1532-429X-18-S1-W14"},{"key":"2025100511581099000_60.9.850.23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009430","article-title":"Myocardial storage, inflammation, and cardiac phenotype in fabry disease after one year of enzyme replacement therapy","volume":"12","author":"Nordin","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025100511581099000_60.9.850.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02381-0"},{"key":"2025100511581099000_60.9.850.25","unstructured":"Al-Sunduqchi Mahdi S . Determining the appropriate sample size for inferences based on the Wilcoxon statistics. Ph.D. dissertation under the direction of William C Guenther dept of statistics. Laramie, Wyoming: University of Wyoming, 1990."},{"key":"2025100511581099000_60.9.850.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.018"},{"key":"2025100511581099000_60.9.850.27","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2013.53"},{"key":"2025100511581099000_60.9.850.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.794529"},{"key":"2025100511581099000_60.9.850.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.03.020"},{"key":"2025100511581099000_60.9.850.30","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12077"},{"key":"2025100511581099000_60.9.850.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.09.020"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmg-2022-108768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:58:18Z","timestamp":1759690698000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmg-2022-108768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,21]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jmg-2022-108768"],"URL":"https:\/\/doi.org\/10.1136\/jmg-2022-108768","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}